# OnCo record paper-agile-ivosidenib-azacitidine-nejm-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-agile-ivosidenib-azacitidine-nejm-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-agile-ivosidenib-azacitidine-nejm-2022" ;
  schema:name "AGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy"@en ;
  schema:description "Adding the IDH1 inhibitor ivosidenib to azacitidine tripled median survival, from 7.9 to 24 months, in older patients with IDH1-mutated AML."@en ;
  schema:url <https://onco.cc/key-papers/paper-agile-ivosidenib-azacitidine-nejm-2022/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2117344>, <https://clinicaltrials.gov/study/NCT03173248> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2117344> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Montesinos P, Recher C, Vives S, et al." ;
  onco:related <https://onco.cc/key-papers/paper-viale-a-venetoclax-azacitidine-nejm-2020/> ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:drugs <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/venetoclax/> ;
  onco:companies <https://onco.cc/companies/servier/> ;
  onco:terms <https://onco.cc/terms/efs/>, <https://onco.cc/terms/os/> ;
  onco:trials <https://onco.cc/trials/agile/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-trial-enrolment/> ;
  onco:journals <https://onco.cc/journals/nejm/> .